In addition, A switch from an HIF1α-dependent pathway to an HIF2α–dependent system is also brought about by sorafenib, thus resulting in a more robust and adequate tolerance of hepatocellular cancer cells to Sorafenib (Zhu et al., 2017; Méndez-Blanco et al., 2018). Here, HIF1A is linked to hepatocellular carcinoma.